EXACT SCIENCES CORP (EXAS) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-03-23

EXACT SCIENCES CORP (EXAS) — no SEC Form 4 insider filings recorded in the last 90 days. InsiderAlpha tracks every EXAS SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About EXACT SCIENCES CORP (EXAS)

SIC classification	Services-Medical Laboratories (SIC 8071)
SEC CIK	0001124140

Recent EXAS Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-03-23	Condella Sarah	EVP, Human Resources	A — Grant or award	60.4K	$0.00	—	SEC
2026-03-23	Conroy Kevin T	President and CEO	D — Derivative transaction	29.1K	—	—	SEC
2026-03-23	Bloomer Aaron	EVP, Chief Financial Officer	A — Grant or award	89.9K	$0.00	—	SEC
2026-03-23	Bloomer Aaron	EVP, Chief Financial Officer	D — Derivative transaction	417	—	—	SEC
2026-03-23	Condella Sarah	EVP, Human Resources	D — Derivative transaction	6.4K	—	—	SEC
2026-03-23	Conroy Kevin T	President and CEO	D — Derivative transaction	1.40M	—	—	SEC
2026-03-23	Baranick Brian	EVP, GM, Precision Oncology	D — Derivative transaction	795	—	—	SEC
2026-03-23	Herriott James	SVP, General Counsel & Sec	D — Derivative transaction	68.2K	—	—	SEC
2026-03-23	Herriott James	SVP, General Counsel & Sec	D — Derivative transaction	1.8K	—	—	SEC
2026-03-23	Bloomer Aaron	EVP, Chief Financial Officer	D — Derivative transaction	138.7K	—	—	SEC
2026-03-23	Baranick Brian	EVP, GM, Precision Oncology	D — Derivative transaction	137.2K	—	—	SEC
2026-03-23	Condella Sarah	EVP, Human Resources	D — Derivative transaction	191.9K	—	—	SEC
2026-03-23	Baranick Brian	EVP, GM, Precision Oncology	A — Grant or award	33.3K	$0.00	—	SEC
2026-03-23	Conroy Kevin T	President and CEO	A — Grant or award	119.3K	$0.00	—	SEC
2026-03-23	Conroy Kevin T	President and CEO	D — Derivative transaction	46.5K	—	—	SEC

All transactions sourced from SEC EDGAR Form 4 filings for EXACT SCIENCES CORP (EXAS). Updated in real time as new filings are submitted to the SEC.

Recent EXAS Form 8-K Material Events

2026-03-23 — Item 1.01, 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01 · Acquisition · neutral [SEC]
Exact Sciences Corporation completed its merger with Abbott Laboratories, with Exact surviving as a direct wholly owned subsidiary of Abbott. The filing documents supplemental indentures related to Exact's outstanding convertible senior notes in connection with the merger transac
2026-03-20 — Item 8.01 · Acquisition · neutral [SEC]
Exact Sciences has received all required regulatory approvals and clearances for its previously announced merger with Abbott Laboratories. Stockholder approval was obtained on February 20, 2026, and the merger is anticipated to close on March 23, 2026, making Exact a wholly owned
2026-02-20 — Item 5.07 · Acquisition · mixed [SEC]
Exact Sciences Corporation held a special stockholder meeting on February 20, 2026, to vote on its merger with Abbott Laboratories under a Merger Agreement dated November 19, 2025. The Merger Agreement Proposal passed with overwhelming support (128.4M votes for vs. 387K against),

Recent Insider Filings

2026-03-23 — Baranick Brian (EVP, GM, Precision Oncology)
2026-03-23 — Herriott James (SVP, General Counsel & Sec)
2026-03-23 — Bloomer Aaron (EVP, Chief Financial Officer)
2026-03-23 — Condella Sarah (EVP, Human Resources)
2026-03-23 — Conroy Kevin T (President and CEO)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in EXAS insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

EXAS Insider Trading — FAQ

What is the latest insider trade for EXAS?: EXACT SCIENCES CORP (EXAS) had 0 insider filings in the last 90 days, with the most recent on 2026-03-23. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying EXAS stock?: 0 insider purchases of EXAS were filed in the last 90 days.
How many insiders are selling EXAS stock?: 0 insider sales of EXAS were filed in the last 90 days.
Where can I see EXAS SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every EXAS SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Related Companies — Recent Insider Activity

Learn More

Open the live EXAS dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.